{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.8","upperLimit":"4.6","value":"3.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"257"}],"units":"Participants"}],"description":"The PFS was defined as the time from the start of treatment to progressive disease (PD) determined by PI or until death.","dispersionType":"95% Confidence Interval","groups":[{"description":"In Cycle 1, subjects will receive carfilzomib 20 mg/m2 intravenously on Days 1, 2, 8, 9, 15, and 16.If all doses are administered and well-tolerated over the 28-day cycle, beginning with Cycle 2 the dose will escalate to 27 mg/m2 intravenously on Days 1, 2, 8, 9, 15, and 16 for all subsequent cycles.","id":"OG000","title":"Carfilzomib (A1)"}],"paramType":"MEDIAN","populationDescription":"Response-Evaluable Population:\n\n1. had measurable disease at Baseline\n2. received at least 1 dose of carfilzomib\n3. underwent baseline disease response assessments and at least 1 post-baseline disease assessment, or discontinued protocol treatment before Cycle 2 Day 1 due to an AE that was considered to be possibly or probably related to carfilzomib","reportingStatus":"POSTED","timeFrame":"Response assessments same as described in primary outcome measure","title":"Progression-free Survival (A1 Only)","type":"SECONDARY","unitOfMeasure":"months"}